메뉴 건너뛰기




Volumn 21, Issue , 2014, Pages 70-76

Practical guide to the use of radium 223 dichloride

Author keywords

Alpha particle; Castration resistant prostate cancer; Radiopharmaceuticals; Radium 223

Indexed keywords

ANTINEOPLASTIC AGENT; RADIOISOTOPE; RADIUM; RADIUM CHLORIDE RA 223;

EID: 84927565244     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (23)

References (45)
  • 2
    • 84879427246 scopus 로고    scopus 로고
    • Multimodality therapy for patients with high-risk prostate cancer: current status and future directions
    • Zaorsky NG, Trabulsi EJ, Lin J, Den RB. Multimodality therapy for patients with high-risk prostate cancer: current status and future directions. Semin Oncol 2013;40(3):308-321.
    • (2013) Semin Oncol , vol.40 , Issue.3 , pp. 308-321
    • Zaorsky, N.G.1    Trabulsi, E.J.2    Lin, J.3    Den, R.B.4
  • 3
    • 84880675653 scopus 로고    scopus 로고
    • Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials
    • Niraula S, Le LW, Tannock IF. Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. J Clin Oncol 2013;31(16):2029-2036.
    • (2013) J Clin Oncol , vol.31 , Issue.16 , pp. 2029-2036
    • Niraula, S.1    Le, L.W.2    Tannock, I.F.3
  • 4
    • 33644675811 scopus 로고    scopus 로고
    • Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgenreceptor signaling axis
    • Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgenreceptor signaling axis. J Clin Oncol 2005;23(32):8253-8261.
    • (2005) J Clin Oncol , vol.23 , Issue.32 , pp. 8253-8261
    • Scher, H.I.1    Sawyers, C.L.2
  • 5
    • 77952554163 scopus 로고    scopus 로고
    • Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
    • Knudsen KE, Penning TM. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab 2010;21(5):315-3124.
    • (2010) Trends Endocrinol Metab , vol.21 , Issue.5 , pp. 315-3124
    • Knudsen, K.E.1    Penning, T.M.2
  • 6
    • 79957443342 scopus 로고    scopus 로고
    • Abiraterone and increased survival in metastatic prostate cancer
    • de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995-2005.
    • (2011) N Engl J Med , vol.364 , Issue.21 , pp. 1995-2005
    • de Bono, J.S.1    Logothetis, C.J.2    Molina, A.3
  • 7
    • 84872078210 scopus 로고    scopus 로고
    • Abiraterone in metastatic prostate cancer without previous chemotherapy
    • Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368(2):138-148.
    • (2013) N Engl J Med , vol.368 , Issue.2 , pp. 138-148
    • Ryan, C.J.1    Smith, M.R.2    de Bono, J.S.3
  • 8
    • 84866770294 scopus 로고    scopus 로고
    • Increased survival with enzalutamide in prostate cancer after chemotherapy
    • Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187-1197.
    • (2012) N Engl J Med , vol.367 , Issue.13 , pp. 1187-1197
    • Scher, H.I.1    Fizazi, K.2    Saad, F.3
  • 9
    • 77957682309 scopus 로고    scopus 로고
    • Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
    • de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376(9747):1147-1154.
    • (2010) Lancet , vol.376 , Issue.9747 , pp. 1147-1154
    • de Bono, J.S.1    Oudard, S.2    Ozguroglu, M.3
  • 10
    • 4744366279 scopus 로고    scopus 로고
    • Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
    • Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-1512.
    • (2004) N Engl J Med , vol.351 , Issue.15 , pp. 1502-1512
    • Tannock, I.F.1    de Wit, R.2    Berry, W.R.3
  • 11
    • 77955066199 scopus 로고    scopus 로고
    • Sipuleucel-T immunotherapy for castration-resistant prostate cancer
    • Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-422.
    • (2010) N Engl J Med , vol.363 , Issue.5 , pp. 411-422
    • Kantoff, P.W.1    Higano, C.S.2    Shore, N.D.3
  • 12
    • 79958037582 scopus 로고    scopus 로고
    • Bone metastasis in prostate cancer: emerging therapeutic strategies
    • Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol 2011;8(6):357-368.
    • (2011) Nat Rev Clin Oncol , vol.8 , Issue.6 , pp. 357-368
    • Sturge, J.1    Caley, M.P.2    Waxman, J.3
  • 13
    • 84862509374 scopus 로고    scopus 로고
    • Molecular imaging of prostate cancer
    • Fox JJ, Schoder H, Larson SM. Molecular imaging of prostate cancer. Curr Opin Urol 2012;22(4):320-327.
    • (2012) Curr Opin Urol , vol.22 , Issue.4 , pp. 320-327
    • Fox, J.J.1    Schoder, H.2    Larson, S.M.3
  • 14
    • 0028144689 scopus 로고
    • Pain and its treatment in outpatients with metastatic cancer
    • Cleeland CS, Gonin R, Hatfield AK et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994;330(9):592-596.
    • (1994) N Engl J Med , vol.330 , Issue.9 , pp. 592-596
    • Cleeland, C.S.1    Gonin, R.2    Hatfield, A.K.3
  • 15
    • 0034085989 scopus 로고    scopus 로고
    • Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients
    • Bubendorf L, Schopfer A, Wagner U et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000;31(5):578-583.
    • (2000) Hum Pathol , vol.31 , Issue.5 , pp. 578-583
    • Bubendorf, L.1    Schopfer, A.2    Wagner, U.3
  • 16
    • 0033017127 scopus 로고    scopus 로고
    • Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer
    • Sabbatini P, Larson SM, Kremer A et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 1999;17(3):948-957.
    • (1999) J Clin Oncol , vol.17 , Issue.3 , pp. 948-957
    • Sabbatini, P.1    Larson, S.M.2    Kremer, A.3
  • 17
    • 0035125777 scopus 로고    scopus 로고
    • Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer
    • Turner SL, Gruenewald S, Spry N, Gebski V. Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. Br J Cancer 2001;84(3):297-302.
    • (2001) Br J Cancer , vol.84 , Issue.3 , pp. 297-302
    • Turner, S.L.1    Gruenewald, S.2    Spry, N.3    Gebski, V.4
  • 18
    • 0027252452 scopus 로고
    • Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer
    • Porter AT, McEwan AJ, Powe JE et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993;25(5):805-813.
    • (1993) Int J Radiat Oncol Biol Phys , vol.25 , Issue.5 , pp. 805-813
    • Porter, A.T.1    McEwan, A.J.2    Powe, J.E.3
  • 19
    • 0038503580 scopus 로고    scopus 로고
    • Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a doubleblind randomized study
    • Smeland S, Erikstein B, Aas M, Skovlund E, Hess SL, Fossa SD. Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a doubleblind randomized study. Int J Radiat Oncol Biol Phys 2003;56(5): 1397-1404.
    • (2003) Int J Radiat Oncol Biol Phys , vol.56 , Issue.5 , pp. 1397-1404
    • Smeland, S.1    Erikstein, B.2    Aas, M.3    Skovlund, E.4    Hess, S.L.5    Fossa, S.D.6
  • 20
    • 0142259750 scopus 로고    scopus 로고
    • Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group
    • Oosterhof GO, Roberts JT, de Reijke TM et al. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol 2003;44(5):519-526.
    • (2003) Eur Urol , vol.44 , Issue.5 , pp. 519-526
    • Oosterhof, G.O.1    Roberts, J.T.2    de Reijke, T.M.3
  • 21
    • 0028233520 scopus 로고
    • A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer
    • Quilty PM, Kirk D, Bolger JJ et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994;31(1):33-40.
    • (1994) Radiother Oncol , vol.31 , Issue.1 , pp. 33-40
    • Quilty, P.M.1    Kirk, D.2    Bolger, J.J.3
  • 22
    • 0036152138 scopus 로고    scopus 로고
    • Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial
    • Sciuto R, Festa A, Rea S et al. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 2002;43(1):79-86.
    • (2002) J Nucl Med , vol.43 , Issue.1 , pp. 79-86
    • Sciuto, R.1    Festa, A.2    Rea, S.3
  • 23
    • 0025781809 scopus 로고
    • A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone
    • Lewington VJ, McEwan AJ, Ackery DM et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991; 27(8):954-958.
    • (1991) Eur J Cancer , vol.27 , Issue.8 , pp. 954-958
    • Lewington, V.J.1    McEwan, A.J.2    Ackery, D.M.3
  • 24
    • 0031954325 scopus 로고    scopus 로고
    • Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial
    • Serafini AN, Houston SJ, Resche I et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998;16(4):1574-1581.
    • (1998) J Clin Oncol , vol.16 , Issue.4 , pp. 1574-1581
    • Serafini, A.N.1    Houston, S.J.2    Resche, I.3
  • 25
    • 2342509633 scopus 로고    scopus 로고
    • Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormonerefractory prostate cancer
    • Sartor O, Reid RH, Hoskin PJ et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormonerefractory prostate cancer. Urology 2004;63(5):940-945.
    • (2004) Urology , vol.63 , Issue.5 , pp. 940-945
    • Sartor, O.1    Reid, R.H.2    Hoskin, P.J.3
  • 26
    • 0031417685 scopus 로고    scopus 로고
    • A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases
    • Resche I, Chatal JF, Pecking A et al. A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 1997;33(10):1583-1591.
    • (1997) Eur J Cancer , vol.33 , Issue.10 , pp. 1583-1591
    • Resche, I.1    Chatal, J.F.2    Pecking, A.3
  • 27
    • 0036733694 scopus 로고    scopus 로고
    • The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study
    • Han SH, de Klerk JM, Tan S et al. The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study. J Nucl Med 2002;43(9):1150-1156.
    • (2002) J Nucl Med , vol.43 , Issue.9 , pp. 1150-1156
    • Han, S.H.1    de Klerk, J.M.2    Tan, S.3
  • 28
    • 0025950294 scopus 로고
    • Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo
    • Maxon HR, 3rd, Schroder LE, Hertzberg VS et al. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. J Nucl Med 1991;32(10):1877-1881.
    • (1991) J Nucl Med , vol.32 , Issue.10 , pp. 1877-1881
    • Maxon, H.R.1    Schroder, L.E.2    Hertzberg, V.S.3
  • 29
    • 84874543674 scopus 로고    scopus 로고
    • Two-year survival followup of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castrationresistant prostate cancer and bone metastases
    • Nilsson S, Franzen L, Parker C et al. Two-year survival followup of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castrationresistant prostate cancer and bone metastases. Clin Genitourin Cancer 2013;11(1):20-26.
    • (2013) Clin Genitourin Cancer , vol.11 , Issue.1 , pp. 20-26
    • Nilsson, S.1    Franzen, L.2    Parker, C.3
  • 30
    • 20644447798 scopus 로고    scopus 로고
    • First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases
    • Nilsson S, Larsen RH, Fossa SD et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005;11(12):4451-4459.
    • (2005) Clin Cancer Res , vol.11 , Issue.12 , pp. 4451-4459
    • Nilsson, S.1    Larsen, R.H.2    Fossa, S.D.3
  • 31
    • 84858706749 scopus 로고    scopus 로고
    • A randomized, doseresponse, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer
    • Nilsson S, Strang P, Aksnes AK et al. A randomized, doseresponse, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer 2012;48(5): 678-686.
    • (2012) Eur J Cancer , vol.48 , Issue.5 , pp. 678-686
    • Nilsson, S.1    Strang, P.2    Aksnes, A.K.3
  • 32
    • 84880428467 scopus 로고    scopus 로고
    • Alpha emitter radium-223 and survival in metastatic prostate cancer
    • Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369(9):213-223.
    • (2013) N Engl J Med , vol.369 , Issue.9 , pp. 213-223
    • Parker, C.1    Nilsson, S.2    Heinrich, D.3
  • 33
    • 84871926771 scopus 로고    scopus 로고
    • A randomized, doubleblind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer
    • Parker CC, Pascoe S, Chodacki A et al. A randomized, doubleblind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol 2013;63(2):189-197.
    • (2013) Eur Urol , vol.63 , Issue.2 , pp. 189-197
    • Parker, C.C.1    Pascoe, S.2    Chodacki, A.3
  • 34
    • 84867676607 scopus 로고    scopus 로고
    • Bone-targeted agents: preventing skeletal complications in prostate cancer
    • Morgans AK, Smith MR. Bone-targeted agents: preventing skeletal complications in prostate cancer. Urol Clin North Am 2012;39(4):533-546.
    • (2012) Urol Clin North Am , vol.39 , Issue.4 , pp. 533-546
    • Morgans, A.K.1    Smith, M.R.2
  • 35
    • 0032455216 scopus 로고    scopus 로고
    • Cancer and bone
    • Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998; 19(1):18-54.
    • (1998) Endocr Rev , vol.19 , Issue.1 , pp. 18-54
    • Guise, T.A.1    Mundy, G.R.2
  • 36
    • 84871253334 scopus 로고    scopus 로고
    • Use of radionuclides in metastatic prostate cancer: pain relief and beyond
    • Vengalil S, O'Sullivan JM, Parker CC. Use of radionuclides in metastatic prostate cancer: pain relief and beyond. Curr Opin Support Palliat Care 2012;6(3):310-315.
    • (2012) Curr Opin Support Palliat Care , vol.6 , Issue.3 , pp. 310-315
    • Vengalil, S.1    O'Sullivan, J.M.2    Parker, C.C.3
  • 37
    • 0027491534 scopus 로고
    • Strontium-89-precursor targeted therapy for pain relief of blastic metastatic disease
    • Robinson RG. Strontium-89-precursor targeted therapy for pain relief of blastic metastatic disease. Cancer 1993;72(11): 3433-3435.
    • (1993) Cancer , vol.72 , Issue.11 , pp. 3433-3435
    • Robinson, R.G.1
  • 38
    • 0022881267 scopus 로고
    • Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate
    • Blake GM, Zivanovic MA, McEwan AJ, Ackery DM. Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 1986;12(9):447-454.
    • (1986) Eur J Nucl Med , vol.12 , Issue.9 , pp. 447-454
    • Blake, G.M.1    Zivanovic, M.A.2    McEwan, A.J.3    Ackery, D.M.4
  • 39
    • 19944386284 scopus 로고    scopus 로고
    • Radioisotopes for the palliation of metastatic bone cancer: a systematic review
    • Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 2005;6(6):392-400.
    • (2005) Lancet Oncol , vol.6 , Issue.6 , pp. 392-400
    • Finlay, I.G.1    Mason, M.D.2    Shelley, M.3
  • 40
    • 0024803298 scopus 로고
    • A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases
    • Turner JH, Claringbold PG, Hetherington EL, Sorby P, Martindale AA. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. J Clin Oncol 1989;7(12): 1926-1931.
    • (1989) J Clin Oncol , vol.7 , Issue.12 , pp. 1926-1931
    • Turner, J.H.1    Claringbold, P.G.2    Hetherington, E.L.3    Sorby, P.4    Martindale, A.A.5
  • 41
    • 11244281049 scopus 로고    scopus 로고
    • The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain
    • Liepe K, Runge R, Kotzerke J. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain. J Cancer Res Clin Oncol 2005;131(1):60-66.
    • (2005) J Cancer Res Clin Oncol , vol.131 , Issue.1 , pp. 60-66
    • Liepe, K.1    Runge, R.2    Kotzerke, J.3
  • 42
    • 34447545672 scopus 로고    scopus 로고
    • A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases
    • Liepe K, Kotzerke J. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun 2007;28(8): 623-630.
    • (2007) Nucl Med Commun , vol.28 , Issue.8 , pp. 623-630
    • Liepe, K.1    Kotzerke, J.2
  • 43
    • 34247636849 scopus 로고    scopus 로고
    • 89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma
    • Baczyk M, Czepczynski R, Milecki P, Pisarek M, Oleksa R, Sowinski J. 89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Nucl Med Commun 2007;28(4):245-250.
    • (2007) Nucl Med Commun , vol.28 , Issue.4 , pp. 245-250
    • Baczyk, M.1    Czepczynski, R.2    Milecki, P.3    Pisarek, M.4    Oleksa, R.5    Sowinski, J.6
  • 44
    • 33746707858 scopus 로고    scopus 로고
    • High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?
    • Bruland OS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res 2006;12(20 Pt 2):6250s-6257s.
    • (2006) Clin Cancer Res , vol.12 , Issue.20 , pp. 6250s-6257s
    • Bruland, O.S.1    Nilsson, S.2    Fisher, D.R.3    Larsen, R.H.4
  • 45
    • 34347244905 scopus 로고    scopus 로고
    • Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study
    • Nilsson S, Franzen L, Parker C et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007;8(7):587-594.
    • (2007) Lancet Oncol , vol.8 , Issue.7 , pp. 587-594
    • Nilsson, S.1    Franzen, L.2    Parker, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.